HK1110207A1 - Ophthalmic compositions and methods of using the same - Google Patents

Ophthalmic compositions and methods of using the same

Info

Publication number
HK1110207A1
HK1110207A1 HK08100863.6A HK08100863A HK1110207A1 HK 1110207 A1 HK1110207 A1 HK 1110207A1 HK 08100863 A HK08100863 A HK 08100863A HK 1110207 A1 HK1110207 A1 HK 1110207A1
Authority
HK
Hong Kong
Prior art keywords
methods
ophthalmic compositions
compositions
ketotifen
same
Prior art date
Application number
HK08100863.6A
Other languages
English (en)
Inventor
Kenneth E Green
George E Minno
Susan Caballa
Original Assignee
Bausch & Lomb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/972,571 external-priority patent/US20060089384A1/en
Application filed by Bausch & Lomb filed Critical Bausch & Lomb
Publication of HK1110207A1 publication Critical patent/HK1110207A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK08100863.6A 2004-10-25 2008-01-23 Ophthalmic compositions and methods of using the same HK1110207A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/972,571 US20060089384A1 (en) 2004-10-25 2004-10-25 Ophthalmic compositions and methods of using the same
US62375804P 2004-10-29 2004-10-29
PCT/US2005/038186 WO2006047418A1 (fr) 2004-10-25 2005-10-24 Compositions ophtalmiques et methodes d'utilisation de ces compositions

Publications (1)

Publication Number Publication Date
HK1110207A1 true HK1110207A1 (en) 2008-07-11

Family

ID=36228119

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08100863.6A HK1110207A1 (en) 2004-10-25 2008-01-23 Ophthalmic compositions and methods of using the same

Country Status (14)

Country Link
US (2) US20060148899A1 (fr)
EP (1) EP1845983B1 (fr)
JP (1) JP4980226B2 (fr)
KR (1) KR101252310B1 (fr)
CN (1) CN101087607B (fr)
AT (1) ATE463244T1 (fr)
AU (1) AU2005299696B2 (fr)
BR (1) BRPI0517451A (fr)
CA (1) CA2585266C (fr)
DE (1) DE602005020513D1 (fr)
ES (1) ES2341789T3 (fr)
HK (1) HK1110207A1 (fr)
MX (1) MX2007004905A (fr)
WO (1) WO2006047418A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070208058A1 (en) * 2004-10-25 2007-09-06 Bryant Roy W Stable Pharmaceutical Compositions and Methods of Making and Using Same
US20090005362A1 (en) * 2007-06-26 2009-01-01 Vo Toan P Compositions Comprising Antihistamines or Mast Cell Stabilizers, and Methods of Making and Using Same
WO2009074853A2 (fr) * 2007-12-10 2009-06-18 Promed Research Centre Composition ophtalmique comprenant de la phényléphrine
US20100087550A1 (en) 2008-10-06 2010-04-08 Zora Marlowe Formulations with a Tertiary Amine Oxide
US8741930B2 (en) * 2008-10-24 2014-06-03 Bridge Pharma, Inc. Treating xerophthalmia with norketotifen
US8765787B2 (en) * 2008-11-21 2014-07-01 Bridge Pharma, Inc. Methods of treatment of xerophthalmia with self-preserving ocular formulations of norketotifen
US20100240624A1 (en) * 2009-03-17 2010-09-23 Aciex Therapeutics, Inc. Ophthalmic Formulations of Ketotifen and Methods of Use
JP7014508B2 (ja) 2016-08-08 2022-02-01 シャープ株式会社 自律走行装置及び自律走行制御方法と制御プログラム
CA3209420A1 (fr) 2021-02-24 2022-09-01 Peter Jarrett Dispositif d'insertion de depot intracanaliculaire
WO2024028816A1 (fr) 2022-08-04 2024-02-08 Bausch + Lomb Ireland Limited Composition ophtalmique comprenant de la pilocarpine et un agent de réduction de la rougeur
WO2024028815A1 (fr) 2022-08-04 2024-02-08 Bausch + Lomb Ireland Limited Composition ophtalmique contenant un anti-allergène et un agent de réduction de rougeur

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH656884A5 (de) * 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
US4826871A (en) * 1985-03-13 1989-05-02 Gressel Philip D Topical ophthalmic compositions containing one or more retinoids
JPS62277323A (ja) * 1986-02-19 1987-12-02 Sankyo Co Ltd フマル酸ケトチフエン含有点眼液の製法
US5756450A (en) * 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US5019591A (en) * 1989-02-17 1991-05-28 Pennsylvania Research Corporation Method for treating retinopathy and other small vessel disorders associated with diabetes
EP0938896A1 (fr) * 1998-01-15 1999-09-01 Novartis AG Compositions pharmaceutiques autoclavables contenant des agents de chelation
ID26033A (id) * 1998-04-02 2000-11-16 Novartis Ag Metode penstabilan komposisi bahan farmasi dengan penggunaan khusus dari antioksidan
US6274626B1 (en) * 1998-12-22 2001-08-14 Bausch & Lomb Incorporated Pheniramine-containing compositions and method for treating allergic responses
US6174859B1 (en) * 1999-04-06 2001-01-16 J & D Sciences, Inc. Method of treatment
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6777429B1 (en) * 1999-07-23 2004-08-17 Novartis Ag Ophthalmic composition
US20040097486A1 (en) * 1999-11-18 2004-05-20 Yanni John M. Use of an H1 antagonist and a safe steroid to treat eye conditions
BR0015647A (pt) * 1999-11-18 2002-07-16 Alcon Inc Uso de um antagonista de h1 e um esteróide seguro para tratar condições dos olhos
US6395756B2 (en) * 1999-12-23 2002-05-28 Novartis Ag Use of ophthalmic agent
US6531128B1 (en) * 2000-02-08 2003-03-11 Pharmacia Corporation Methods for treating glaucoma
JP3450805B2 (ja) * 2000-08-08 2003-09-29 わかもと製薬株式会社 水性医薬組成物
US6515006B2 (en) * 2000-11-08 2003-02-04 Hmt Pharma, Inc. Ophthalmic formulation which modulates dilation
AR034372A1 (es) * 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
US20040198828A1 (en) * 2003-01-17 2004-10-07 Abelson Mark B. Combinational use of long-acting and short-acting anti-histamines for ocular allergies

Also Published As

Publication number Publication date
EP1845983A1 (fr) 2007-10-24
CA2585266A1 (fr) 2006-05-04
KR20070074635A (ko) 2007-07-12
KR101252310B1 (ko) 2013-04-08
CN101087607A (zh) 2007-12-12
ES2341789T3 (es) 2010-06-28
AU2005299696A1 (en) 2006-05-04
CA2585266C (fr) 2010-10-19
ATE463244T1 (de) 2010-04-15
CN101087607B (zh) 2010-07-28
US20060148899A1 (en) 2006-07-06
BRPI0517451A (pt) 2008-10-07
JP2008517937A (ja) 2008-05-29
WO2006047418A1 (fr) 2006-05-04
MX2007004905A (es) 2007-10-15
JP4980226B2 (ja) 2012-07-18
EP1845983A4 (fr) 2008-03-12
DE602005020513D1 (de) 2010-05-20
EP1845983B1 (fr) 2010-04-07
AU2005299696B2 (en) 2012-01-12
US20120004265A1 (en) 2012-01-05

Similar Documents

Publication Publication Date Title
HK1110207A1 (en) Ophthalmic compositions and methods of using the same
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
ATE494893T1 (de) Sulfonamide, sulfamate und sulfamide als gamma- secretase-hemmer
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
ATE464303T1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
MX2007004264A (es) Uso de inhibidores de cinasas jun n-terminales para el tratamiento de retinopat??a glaucomatosa y enfermedades oculares.
ATE368031T1 (de) Neue gamma secretase inhibitoren
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
WO2005123093A3 (fr) Formulations ophtalmiques comprenant des antagonistes selectifs des recepteurs alpha 1
DK1780197T3 (da) 5-Substituerede 2-phenylamino-benzamider som MEK-inhibitorer
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
ATE355075T1 (de) Behandlung der glykogenspeicherkrankheit typ ii
EA200700109A1 (ru) Способы лечения офтальмологических состояний (варианты)
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
ATE320803T1 (de) Verfahren zur behandlung von alzheimerschen krankheit
DE602004012578D1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
ATE451361T1 (de) Materialien und methoden zur behandlung von koagulationsstörungen
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
TR200400526T4 (tr) Göz kurumasının tedavisi için lipoksin A4 ve analogları
RU2008102249A (ru) Профилактический или терапевтичесский агент для корнеального /конъюнктивального заболевания
EA200701017A1 (ru) Применение рибозы-цистеина для лечения гипоксии
BRPI0417476A (pt) derivados de indol hidroxietilamina tricìclica e seu uso no tratamento da doença de alzheimer